Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model. 28953502 2018
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. 28314589 2017
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells. 26294741 2016
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE We, for the first time, report the molecular mechanisms by which AP24534 exerts antitumor effects on ECs with FGFR2 activating mutations, which would provide mechanistic insight into ongoing clinical investigations of AP24534 for ECs. 26574622 2016
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE For example, we identified both known and new endometrial cancer hotspots in the tyrosine kinase domain of the FGFR2 protein, one of which is also a hotspot in breast cancer, and found new two hotspots in the Immunoglobulin I-set domain in colon cancer. 25794154 2016
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE Of 248 patients with FGFR2 prescreening results, 27 (11%) had FGFR2(mut) endometrial cancer. 25981814 2015
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 AlteredExpression disease BEFREE EC cell lines expressing wild-type FGFR2 were relatively resistant to all inhibitors, whereas EC cell lines expressing mutated FGFR2 showed differential sensitivity. 23908597 2014
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE These findings suggest that combinatory therapies using dovitinib plus ICI182.780 treatment can be truly effective in patients with endometrial carcinomas carrying FGFR2 mutations. 24448819 2014
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 AlteredExpression disease BEFREE Dovitinib may have antitumor activity in endometrial cancer beyond FGFR2-mutated cases and may permit greater flexibility in patient selection. 23443805 2013
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. 23468082 2013
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Finally, the identification of 3 likely activating mutations in the tyrosine kinase receptor FGFR2, analogous to those reported in ovarian and endometrial carcinoma, point to potential therapeutic avenues for a subset of cases. 23778141 2013
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE FGFR2 alterations in endometrial carcinoma. 21725289 2012
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE Recent studies have shown that anti-fibroblast growth factor receptor 2 agents inhibit tumor progression in various human cancers, such as endometrial carcinoma and gastric carcinoma, which remains one of the most frequent causes of cancer-related death worldwide. 22440694 2012
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE Mutations in multiple oncogenes including KRAS, CTNNB1, PIK3CA and FGFR2 have been identified in endometrial cancer. 22383975 2012
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease CTD_human Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. 21936542 2012
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE Mutational activation of one member of this receptor family, FGFR2, is a frequent event in endometrioid endometrial cancer. 20106510 2010
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Taken into account with our recent discovery of activating FGFR2 mutations in endometrial cancer, we suggest that FGFR2 may join the list of genes that play context-dependent opposing roles in cancer. 19147536 2009
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE We also observed a nonsignificant inverse association with rs889312 (MAP3K1) variant carriers [OR = 0.85 (95% CI: 0.68-1.05)] and rs1219648 (FGFR2) variant carriers [OR= 0.86 (95% CI: 0.69-1.06) and endometrial cancer risk. 18785201 2009
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 AlteredExpression disease BEFREE Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. 18757403 2008
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 CausalMutation disease CLINVAR Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. 17525745 2007
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. 17525745 2007
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 CausalMutation disease CLINVAR The discovery of activating FGFR2 mutations in endometrial carcinoma raises the possibility of employing anti-FGFR molecularly targeted therapies in patients with advanced or recurrent endometrial carcinoma. 17525745 2007
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 CausalMutation disease CLINVAR Apert syndrome with preaxial polydactyly showing the typical mutation Ser252Trp in the FGFR2 gene. 16440883 2006
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 CausalMutation disease CLINVAR Beare-Stevenson syndrome: Two South American patients with FGFR2 analysis. 12900900 2004
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 CausalMutation disease CLINVAR Mutation in the FGFR2 gene in a Taiwanese patient with Beare-Stevenson cutis gyrata syndrome. 12000365 2002